Arcus Biosciences, Inc.
Tremor tracks 8 of its cancer trials.
Company-wide warning signs
These add points to every one of this company's trials.
Trials
- RCUSArcus Biosciences, Inc.10Calm
Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer
FinishedPhase 2151 patientsMain results: Jul 9, 2025 - RCUSArcus Biosciences, Inc.10Calm
An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.
FinishedPhase 1/2227 patientsMain results: Sep 5, 2025 - RCUSArcus Biosciences, Inc.10Calm
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer
FinishedPhase 1/2173 patientsMain results: Aug 30, 2024 - RCUSArcus Biosciences, Inc.0Calm
Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Running, no new patientsPhase 3610 patientsMain results: Nov 30, 2030 - RCUSArcus Biosciences, Inc.0Calm
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
Signing up patientsPhase 3720 patientsMain results: Apr 2028 - RCUSArcus Biosciences, Inc.0Calm
A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies
FinishedPhase 2332 patientsMain results: Sep 7, 2026 - RCUSArcus Biosciences, Inc.0Calm
Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer
FinishedPhase 2169 patientsMain results: Sep 17, 2026 - RCUSArcus Biosciences, Inc.0Calm
A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body
FinishedPhase 31,040 patientsMain results: Aug 28, 2026
Key executives leaving
From the last 12 months of the company's SEC reports.
Insider trades (last 6 months)
“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.
10 sales (0 not pre-planned) · 0 purchases
- Azoy AlexanderChief Accounting Officer · Aug 21, 2026Sold 2,827 sharesabout $85 thousand · pre-planned
- Jaen Juan C.President · Jul 10, 2026Sold 19,799 sharesabout $566 thousand · pre-planned
- Jaen Juan C.President · Jul 10, 2026Sold 268 sharesabout $8 thousand · pre-planned
- Jaen Juan C.President · Jul 9, 2026Sold 48,502 sharesabout $1.5 million · pre-planned
- Jaen Juan C.President · Jun 24, 2026Sold 6,431 sharesabout $191 thousand · pre-planned
- Jaen Juan C.President · Jun 23, 2026
Recent SEC filings
Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.